Preventative Care through PHQ-9

Early Detection and Risk Stratification

The American College of Physicians recommends initial screening with the PHQ-2, which has a sensitivity of 73.7% and specificity of 75.2% for detecting major depressive disorder, allowing rapid identification of at-risk patients before symptoms worsen 1
Patients scoring 2-3 on the PHQ-2 should proceed to the full 9-item assessment, creating a two-stage approach that efficiently identifies those requiring further evaluation while minimizing screening burden on low-risk individuals 2, 3
The full PHQ-9 demonstrates strong diagnostic accuracy with sensitivity of 89.5% and specificity of 77.5% at a cutoff score of 11, though a lower threshold of 8 may be more appropriate in certain populations such as cancer patients 1, 2

The American Psychiatric Association recommends that mild symptomatology (scores 1-7) prompts education and resource provision rather than watchful waiting, ensuring patients develop adequate coping skills and access to social support before symptoms escalate 2, 3
Moderate symptoms (scores 8-14) trigger consultation with psychology or psychiatry for diagnostic confirmation, preventing the common pitfall of untreated subthreshold depression progressing to major depressive disorder 1, 2, 3
Moderate-to-severe or severe symptoms (scores 15-27) mandate immediate referral to mental health specialists, preventing the substantial functional impairment and mortality risk associated with untreated severe depression 1, 2, 3

The National Institute of Mental Health recommends that item 9 specifically assesses thoughts of self-harm, enabling detection of suicidal ideation that requires emergency intervention regardless of total score 1, 2, 3
Any endorsement of self-harm thoughts triggers immediate safety assessment and referral for emergency evaluation by a licensed mental health professional, preventing suicide attempts and completed suicides 2, 3

The American Medical Association recommends repeat administration of the PHQ-9 at 3, 6, and 12 months after treatment initiation, allowing early detection of inadequate response or relapse, with a minimal clinically important difference of 5 points indicating meaningful change 1
Persistent moderate scores (8-14) after 4-6 weeks of treatment indicate need for dose optimization or treatment modification, preventing the morbidity associated with prolonged inadequate treatment 4

The American Academy of Pediatrics recommends universal screening beginning at age 12 years and continuing through age 18, as this represents the period when depression onset accelerates and validated treatments exist 1
The 2-week symptom timeframe captures clinically significant episodes while avoiding over-detection of transient mood fluctuations that do not require intervention 1

The American College of Physicians recommends never screening without established protocols for managing positive screens, as screening alone without intervention pathways does not improve outcomes and wastes resources 1, 5
Recognize that false-positive rates reach 60-76% in primary care settings where depression prevalence is 5-10%, meaning positive screens require diagnostic confirmation rather than automatic treatment initiation 5

The American Psychiatric Association recommends incorporating pertinent history, risk factors, sociodemographic factors, psychiatric comorbidities, and symptom duration to distinguish true depression from medical conditions, substance effects, or normal grief reactions 1, 5
Screen for bipolar disorder before initiating or increasing antidepressants in patients with elevated PHQ-9 scores, as undiagnosed bipolar disorder can lead to manic episodes, rapid cycling, or mixed states when treated with antidepressants alone 4